Naomi A Lavan1, Dara O Kavanagh2, Joseph Martin3, Cormac Small3, Myles R Joyce4, Clare M Faul5, Paul J Kelly6, Michael O'Riordain7, Charles M Gillham1, John G Armstrong5, Osama Salib1, Deborah A McNamara8, Gerard McVey1, Brian D P O'Neill1. 1. 1 St Luke's Radiation Oncology Network, Dublin, Ireland. 2. 2 St Vincent's University Hospital, Dublin, Ireland. 3. 3 Department of Radiation Oncology, University College Hospital Galway, Galway, Ireland. 4. 4 Department of Surgery, University College Hospital Galway, Galway, Ireland. 5. 5 St Luke's Institute of Cancer Research, Dublin, Ireland. 6. 6 Department of Radiation Oncology, Cork University Hospital, Cork, Ireland. 7. 7 Department of Surgery, Cork University Hospital, Cork, Ireland. 8. 8 Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.
Abstract
OBJECTIVE: Neoadjuvant "long-course" chemoradiation is considered a standard of care in locally advanced rectal cancer. In addition to prostatectomy, external beam radiotherapy and brachytherapy with or without androgen suppression (AS) are well established in prostate cancer management. A retrospective review of ten cases was completed to explore the feasibility and safety of applying these standards in patients with dual pathology. To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. METHODS: Eligible patients had synchronous histologically proven locally advanced rectal cancer (defined as cT3-4Nx; cTxN1-2) and non-metastatic prostate cancer (pelvic nodal disease permissible). Curative treatment was delivered to both sites simultaneously. Follow-up was as per institutional guidelines. Acute and late toxicities were reviewed, and a literature search performed. RESULTS: Pelvic external beam radiotherapy (RT) 45-50.4 Gy was delivered concurrent with 5-fluorouracil (5FU). Prostate total dose ranged from 70.0 to 79.2 Gy. No acute toxicities occurred, excluding AS-induced erectile dysfunction. Nine patients proceeded to surgery, and one was managed expectantly. Three relapsed with metastatic colorectal cancer, two with metastatic prostate cancer. Five patients have no evidence of recurrence, and four remain alive with metastatic disease. With a median follow-up of 2.2 years (range 1.2-6.3 years), two significant late toxicities occurred; G3 proctitis in a patient receiving palliative bevacizumab and a G3 anastomotic stricture precluding stoma reversal. CONCLUSION: Patients proceeding to synchronous radical treatment of both primary sites should receive 45-50.4 Gy pelvic RT with infusional 5FU. Prostate dose escalation should be given with due consideration to the potential impact of prostate cancer on patient survival, as increasing dose may result in significant late morbidity. Review of published series explores the possibility of prostate brachytherapy as an alternative method of boost delivery. Frequent use of bevacizumab in metastatic rectal cancer may compound late rectal morbidity in this cohort. ADVANCES IN KNOWLEDGE: To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. This article contributes to the understanding of how best to approach definitive treatment in these patients.
OBJECTIVE: Neoadjuvant "long-course" chemoradiation is considered a standard of care in locally advanced rectal cancer. In addition to prostatectomy, external beam radiotherapy and brachytherapy with or without androgen suppression (AS) are well established in prostate cancer management. A retrospective review of ten cases was completed to explore the feasibility and safety of applying these standards in patients with dual pathology. To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. METHODS: Eligible patients had synchronous histologically proven locally advanced rectal cancer (defined as cT3-4Nx; cTxN1-2) and non-metastatic prostate cancer (pelvic nodal disease permissible). Curative treatment was delivered to both sites simultaneously. Follow-up was as per institutional guidelines. Acute and late toxicities were reviewed, and a literature search performed. RESULTS: Pelvic external beam radiotherapy (RT) 45-50.4 Gy was delivered concurrent with 5-fluorouracil (5FU). Prostate total dose ranged from 70.0 to 79.2 Gy. No acute toxicities occurred, excluding AS-induced erectile dysfunction. Nine patients proceeded to surgery, and one was managed expectantly. Three relapsed with metastatic colorectal cancer, two with metastatic prostate cancer. Five patients have no evidence of recurrence, and four remain alive with metastatic disease. With a median follow-up of 2.2 years (range 1.2-6.3 years), two significant late toxicities occurred; G3 proctitis in a patient receiving palliative bevacizumab and a G3 anastomotic stricture precluding stoma reversal. CONCLUSION:Patients proceeding to synchronous radical treatment of both primary sites should receive 45-50.4 Gy pelvic RT with infusional 5FU. Prostate dose escalation should be given with due consideration to the potential impact of prostate cancer on patient survival, as increasing dose may result in significant late morbidity. Review of published series explores the possibility of prostate brachytherapy as an alternative method of boost delivery. Frequent use of bevacizumab in metastatic rectal cancer may compound late rectal morbidity in this cohort. ADVANCES IN KNOWLEDGE: To our knowledge, this is the largest case series of synchronous rectal and prostate cancers treated with curative intent. This article contributes to the understanding of how best to approach definitive treatment in these patients.
Authors: Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-31 Impact factor: 7.038
Authors: D O Kavanagh; D M Quinlan; J G Armstrong; J M P Hyland; P R O'Connell; D C Winter Journal: Int J Colorectal Dis Date: 2012-03-28 Impact factor: 2.571
Authors: Athanasios Colonias; Lloyd Farinash; Linda Miller; Sandra Jones; David S Medich; Larisa Greenberg; Ralph Miller; David S Parda Journal: Nat Clin Pract Oncol Date: 2005-05
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-01 Impact factor: 7.038
Authors: Giuseppe Celentano; Massimiliano Creta; Luigi Napolitano; Marco Abate; Roberto La Rocca; Marco Capece; Claudia Mirone; Simone Morra; Francesco Di Bello; Luigi Cirillo; Francesco Mangiapia; Gianluigi Califano; Claudia Collà Ruvolo; Caterina Sagnelli; Antonello Sica; Armando Calogero; Fabrizio Iacono; Ferdinando Fusco; Vincenzo Mirone; Nicola Longo Journal: Diagnostics (Basel) Date: 2022-06-15
Authors: Corbin D Jacobs; Jacob Trotter; Manisha Palta; Michael J Moravan; Yuan Wu; Christopher G Willett; W Robert Lee; Brian G Czito Journal: Front Oncol Date: 2020-03-24 Impact factor: 6.244